Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), retaining the price target of $52.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Michael Ulz has given his Hold rating due to a combination of factors related to Ionis Pharmaceuticals’ recent clinical trial results and future prospects. The Phase 3 Essence study demonstrated promising reductions in triglyceride levels among patients with moderate hypertriglyceridemia, which is a positive indicator for the company’s ongoing research efforts. However, the trial primarily served to build a safety database for future label expansion into more severe cases, and the results, while encouraging, are not yet definitive for broader market applications.
Looking forward, the pivotal CORE and CORE2 studies, expected to conclude in the third quarter of 2025, will be critical in determining the potential for label expansion into severe hypertriglyceridemia. These studies will provide more comprehensive data that could influence Ionis Pharmaceuticals’ market position and potential regulatory submissions. Given the current state of the data and the timeline for future results, a Hold rating reflects a cautious but optimistic outlook, pending further developments.
Ulz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Rhythm Pharmaceuticals. According to TipRanks, Ulz has an average return of -6.0% and a 36.84% success rate on recommended stocks.
In another report released on May 1, Barclays also maintained a Hold rating on the stock with a $51.00 price target.